Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

MorphoSys AG. (12/14/23). "Press Release: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million [Not for US, AU, ZA, JP, et al.]". Planegg.

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group Novartis (Group)
  Group OTHER
Products Product pelabresib (CPI-0610)
  Product 2 investment banking
Index term Index term MorphoSys–SEVERAL: investment, 202312 cash capital increase €102.7m with 3.42m new shares placed with institutional investors at €30/share
Persons Person Kress, Jean-Paul (MorphoSys 201909–202406 CEO before Syntimmune + Biogen + Sanofi Genzyme TERMINATED 6/26)
  Person 2 Biegi, Thomas (MorphoSys 202012– Head of Corporate Communications before Pfizer + Daimler)

Record changed: 2024-01-20


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Novartis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top